Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism
about
FGF23 in Acute and Chronic IllnessAre there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular DiseaseFGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease.Fibroblast Growth Factor-23-A Potential Uremic ToxinThe use of fibroblast growth factor 23 testing in patients with kidney disease.Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjectsCinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled studyEffects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis.Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency.FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysisUpdate on fibroblast growth factor 23 in chronic kidney disease.Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.Changes in jawbones of male patients with chronic renal failure on digital panoramic radiographs.Fibroblast growth factor 23 and bone mineralisation.Phosphate Toxicity in CKD: The Killer among UsFibroblast growth factor-23: what we know, what we don't know, and what we need to know.A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5/6 nephrectomized rats.Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism.Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative reviewFGF23 and PTH--double agents at the heart of CKD.The role of FGF23 in CKD--with or without Klotho.The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications.Cinacalcet hydrochloride for the treatment of hyperparathyroidism.FGF-23 and secondary hyperparathyroidism in chronic kidney disease.Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.Defective skeletal mineralization in pediatric CKD.Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.Advances in pharmacotherapy for secondary hyperparathyroidism.Cinacalcet and Clinical Outcomes in Dialysis.Calcifediol to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.Chronic Kidney Disease-Mineral and Bone Disorder in Asia.FGF23 from bench to bedside.A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemoCalcimimetics and outcomes in CKD.
P2860
Q26778554-2293E15A-CCCE-411F-94F5-15A050563A35Q27002431-4A37A399-58CA-40DE-BDD9-534B2DFF20D6Q27024043-DB72C392-F089-4D60-9B43-1D206505B40EQ27687769-662C4A3E-F23E-4DF4-87E6-B9ED97B989FDQ28075648-6B983013-BC3E-473F-AEFE-0F7D0BC1327DQ33835743-401084EA-F1B4-4BC6-80B9-4AD83E22678EQ34385273-DBB2991A-B187-472E-BF55-18BA144BE896Q34739121-9A2534E4-9432-40E0-8151-97356F4A953BQ35115090-971C1D4F-0605-4468-8F25-5FC732251300Q35232118-6AA68BFB-73C8-42CE-9634-25D4E7F51E92Q35682152-8B2C9DC1-BA08-41CA-AC19-AA0621C73486Q35735678-3E1ADD8D-F4A9-479F-95A0-9EE1AD7EA9BEQ35949319-63048AD8-6226-49B5-ADDC-87EE04A464FCQ36210285-0FF8F55C-4BAA-406F-B8AA-2F5F16C0E628Q36225208-01B22872-6208-4C6C-92C9-C96695D71C19Q36432849-6B721C1B-8980-402B-A38F-28C5D3B939B7Q36667542-D30E8CA5-763C-4FB9-B509-CDD7FC8FD655Q36756061-CB4B71E7-246F-4F95-800E-6C4372721A90Q36965142-8775056E-932D-4F0C-8CEE-F0387160DD0DQ37162723-E6359CF9-2643-495B-A0A3-0C78EB18F58DQ37162734-C2E3F8AC-A0E3-4187-B5F2-106B73A79AA3Q37328071-A4F598C0-28D4-4654-ABDC-0E37B89CDC83Q37412861-8D4FE515-E91E-43BB-AB4E-D4C5AA19DFB1Q37695914-E03664FD-C3F0-4AB9-991C-DE08B4A7ED53Q37996937-4833DBD4-C9F5-41A2-B37C-A2EF41E2F508Q38020094-79784C59-F262-458C-AE94-950145F1CE32Q38053246-88792C8B-D0A3-4E59-83D4-726E69C1AD84Q38085702-CC30DAB1-8175-48BE-A1F9-743E9D83BE43Q38123396-D9C03782-CA10-4474-BF8C-D1A1A20583F5Q38141236-1D354AB3-D1D5-436A-ACAC-DBD2A2835998Q38339007-F486580D-8314-4F6E-8382-EC7A4D723200Q38436799-7AD55B92-C636-4C38-8D8D-855135D5D1DAQ38544533-F6F3728E-EE6B-44AE-AB52-E13F071ED918Q38565049-635CB7FB-2064-458E-B0FB-937752487051Q38605841-ADA81E31-3451-46C0-B7B9-BFC8393B6CF8Q38633258-0CA5D84D-AE3A-420C-AA71-182FF18D74DEQ38635767-05171628-D2BA-44DB-9CE2-609CCD21474AQ38728860-39A54A06-A904-49A2-94BA-B91B15F1B1C5Q39037214-03119219-6D24-45C0-8460-778A4521369BQ42727545-F6183667-2911-45AF-8E73-B5A91E4F4A84
P2860
Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism
description
im Juli 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 05 July 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2012
@uk
name
Cinacalcet treatment and serum ...... secondary hyperparathyroidism
@en
Cinacalcet treatment and serum ...... secondary hyperparathyroidism
@nl
type
label
Cinacalcet treatment and serum ...... secondary hyperparathyroidism
@en
Cinacalcet treatment and serum ...... secondary hyperparathyroidism
@nl
prefLabel
Cinacalcet treatment and serum ...... secondary hyperparathyroidism
@en
Cinacalcet treatment and serum ...... secondary hyperparathyroidism
@nl
P2093
P2860
P356
P1476
Cinacalcet treatment and serum ...... secondary hyperparathyroidism
@en
P2093
Akira Fujimori
Masahiro Koizumi
Shohei Nakanishi
P2860
P304
P356
10.1093/NDT/GFR384
P407
P577
2011-07-05T00:00:00Z